Mexiletine in the treatment of ventricular arrhythmias.
The effect of mexiletine, a new antiarrhythmic drug, was studied by oral (600 to 1200 mg/day) or intravenous (250 mg in 10 minutes) route in 45 patients; most of them had coronary insufficiency. Our results show that mexiletine is a potent ventricular antiarrhythmic drug which is efficient on several types of xylocaine resistant ventricular arrhythmias. In our experience, mexiletine is reliable when administered intravenously; there are frequent and sometimes severe side-effects when given orally.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006323:Heart Arrest / Q000139:chemically induced; D006352:Heart Ventricles; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D011437:Propylamines / Q000627:therapeutic use*
D011437:Propylamines; D008801:Mexiletine